Journals / Çocuk Enfeksiyon Dergisi / 2015 / Cilt: 9 - Sayı: 4

Amfoterisin B Tedavisi Sırasında Artmış Minimum İnhibisyon Konsantrasyonu (MİK) Nedeniyle Beyin Omurilik Sıvısında (BOS) Tekrarlayan Candida albicans Üremeleriyle Giden Şant Enfeksiyonlu Olgu

Persistent Candida albicans Infection of A Cerebrospinal Fluid Shunt Infection Unresponsive to Amphotericin B Treatment Because of Increased Minimum Inhibitory Concentration

Pages
181–184
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein, we present a preterm neonate with persistant Candida albicans cerebrospinal fluid (CSF) shunt infection that was unresponsible to amphotericin B treatment due to increased minimal inhibitory concen- tration (MIC) during the therapy period and later which was treated by voriconazole plus flucytosine. (J Pediatr Inf 2015; 9: 181-4)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Infection is still the most common complication of shunt procedures in children.
📊
Key Findings & Data:However fungal infec- tion is considered to be rare, it is also associated with significant morbidity and mortality.
💡
Conclusion & Impact:Herein, we present a preterm neonate with persistant Candida albicans cerebrospinal fluid (CSF) shunt infection that was unresponsible to amphotericin B treatment due to increased minimal inhibitory concen- tration (MIC) during the therapy period and later which was treated by voriconazole plus flucytosine. (J Pediatr Inf 2015; 9: 181-4)
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Infection is still the most common complication of shunt procedures in children. However fungal infec- tion is considered to be rare, it is also associated with significant morbidity and mortality. The risk is increas- ing in premature neonates and after neurosurgery. Herein, we present a preterm neonate with persistant Candida albicans cerebrospinal fluid (CSF) shunt infection that was unresponsible to amphotericin B treatment due to increased minimal inhibitory concen- tration (MIC) during the therapy period and later which was treated by voriconazole plus flucytosine. (J Pediatr Inf 2015; 9: 181-4)

Özet

Enfeksiyon şant uygulamalarında halen en sık görü- len komplikasyondur. Mantar enfeksiyonları nadir olmakla birlikte ciddi morbidite ve mortalite ile ilişkilidir. Prematüre yenidoğanlarda ve beyin ameliyatlarından sonra bu risk artar. Bu makalede, tedavi sırasında artmış MIC değeri nedeniyle amphoterisin B tedavisi- ne cevap vermeyip vorikonazol ile flusitozin tedavisine cevap veren beyin omurilik sıvısı (BOS)’da tekrarla- yan Candida albicans üremeleri ile giden şant enfek- siyonlu bir olgu sunulmuştur. (J Pediatr Inf 2015; 9: 181-4)

🔖

Cite This Article

KUZDAN, C., KARAASLAN, A., SOYSAL, A., MOUNLA, K., Bakır, M., ÇERİK.İOĞLU, N. (2015). Amfoterisin B Tedavisi Sırasında Artmış Minimum İnhibisyon Konsantrasyonu (MİK) Nedeniyle Beyin Omurilik Sıvısında (BOS) Tekrarlayan Candida albicans Üremeleriyle Giden Şant Enfeksiyonlu Olgu. Çocuk Enfeksiyon Dergisi, Cilt: 9 - Sayı: 4, 181–184. https://ajindex.com/articles/190382

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Chiou CC, Wong TT, Lin HH, et al. Fungal infection of ventriculoperitoneal shunts in children. Clin Infect Dis 1994
  2. [CrossRef] 2. Tunkel AR, Kaufman BA. Cerebrospinal fluid shunt infections. In: Principles and Practice of Infectious Diseases, 6th ed. Mandell GL, Bennett JE, Dolin R, eds. Churchill Livingstone, Philadelphia, 2005. 3. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009
  3. [CrossRef] 4. M. Cruciani, G. Di Perri, M. Molesini, S. Vento, E. Concia, D. Bassetti. Use of fluconazole in the treatment of Candida albicans hydrocephalus shunt infection. Eur J Clin Microbiol Infect Dis 1992
  4. [CrossRef] 5. Sanchez-Portocarrero JP, Saldan CJ, Perzececilia E. Candida cerebrospinal fluid shunt infections: Report of two cases and review of literature. Diag Microbiol Infect Dis 1994
  5. [CrossRef] 6. Viudes A, Cano J, Salavert M, et al. An eight year retrospective study of Candida meningitis ar a tertiary care hospital. Intern Sci Conf Antimicrobial Agents Chemother 2001
  6. Zaoutis TE, Coffin SE. Clinical syndromes of device-associated infections. In: Long SS, Pickering LK, Prober CG (eds). Principles and Practice of Pediatric Infectious Diseases. 3rd ed. Philadelphia, Churchill Livingstone
  7. [CrossRef] 8. Nagata MP, Gentry CA, Hampton EM. Is there a therapeutic or pharmacokinetic rationale for amphotericin B dosing in systemic Candida infections? Ann Pharmacother 1996
  8. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007
  9. [CrossRef] 10. Pfaller MA, Espinel-Ingroff A, Canton E, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 2012
  10. [CrossRef] 11. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003
  11. [CrossRef] 12. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003
  12. [CrossRef] 13. E